Gyre Therapeutics (GYRE) EBITDA Margin (2010 - 2026)
Gyre Therapeutics (GYRE) reported EBITDA Margin of 41.54% for Q1 2026, down 5185.0% year-over-year from 0.82% in Q1 2025, and down 85.34% on a QoQ basis from 22.41% in Q4 2025.
Gyre Therapeutics (GYRE) has 16 years of EBITDA Margin data on file, last reported at 41.54% in Q1 2026.
- Quarterly EBITDA Margin fell 5185.0% year-over-year to 41.54% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7.34% (down 1764.0% YoY) and the FY2025 annual result came in at 2.6%, down 1268.0% from the prior year.
- EBITDA Margin eased to 41.54% in Q1 2026 per GYRE's latest filing, from 22.41% in the prior quarter.
- Across five years, EBITDA Margin topped out at 39.84% in Q3 2023 and bottomed at 1851.51% in Q1 2022.
- The 5-year median for EBITDA Margin is 10.3% (2025), against an average of 139.28%.
- The widest annual swing landed in 2022, when EBITDA Margin tumbled 32200 bps; it then jumped 187824 bps in 2023.
- Tracing GYRE's EBITDA Margin over 5 years: stood at 22.13% in 2022, then tumbled by 1425 bps to 337.53% in 2023, then jumped by 101 bps to 2.39% in 2024, then slumped by 1039 bps to 22.41% in 2025, then sank by 85 bps to 41.54% in 2026.
- Per Business Quant, the three latest GYRE EBITDA Margin figures stand at 41.54% (Q1 2026), 22.41% (Q4 2025), and 22.66% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | -41.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.54% |
| Dec 31, 2025 | -22.41% |
| Sep 30, 2025 | 22.66% |
| Jun 30, 2025 | 8.11% |
| Mar 31, 2025 | 10.30% |
| Dec 31, 2024 | 2.39% |
| Sep 30, 2024 | 16.61% |
| Jun 30, 2024 | 12.66% |
| Mar 31, 2024 | 29.70% |
| Dec 31, 2023 | -337.53% |
| Sep 30, 2023 | 39.84% |
| Jun 30, 2023 | 16.96% |
| Mar 31, 2023 | 26.73% |
| Dec 31, 2022 | -22.13% |
| Mar 31, 2022 | -1,851.51% |
| Dec 31, 2021 | -832.50% |
| Sep 30, 2021 | -1,097.39% |
| Jun 30, 2021 | -1,759.19% |
| Mar 31, 2021 | -1,529.52% |
| Dec 31, 2020 | -927.67% |
| Sep 30, 2020 | -1,802.91% |
| Jun 30, 2020 | -1,047.10% |
| Mar 31, 2020 | -30.97% |
| Mar 31, 2018 | -111,316.67% |
| Dec 31, 2017 | -1,833.02% |
| Sep 30, 2017 | -1,848.43% |
| Jun 30, 2017 | -5,354.95% |
| Mar 31, 2017 | -1,539.11% |
| Dec 31, 2016 | -7,352.11% |
| Sep 30, 2016 | -5,240.37% |
| Jun 30, 2016 | -4,509.17% |
| Mar 31, 2016 | -4,194.50% |
| Dec 31, 2015 | -4,296.33% |
| Sep 30, 2015 | -3,564.22% |
| Jun 30, 2015 | -506.17% |
| Mar 31, 2015 | -1,001.93% |
| Dec 31, 2014 | -696.28% |
| Sep 30, 2014 | -898.54% |
| Jun 30, 2014 | -2,724.58% |
| Mar 31, 2014 | -5,057.24% |
| Dec 31, 2013 | -14,380.65% |
| Mar 31, 2013 | -228.48% |
| Dec 31, 2012 | -2,719.66% |
| Sep 30, 2012 | -1,002.08% |
| Jun 30, 2012 | 42.98% |
| Mar 31, 2012 | 10.72% |
| Dec 31, 2011 | -53.55% |
| Sep 30, 2011 | -49.23% |
| Jun 30, 2011 | -12.39% |
| Mar 31, 2011 | 32.80% |
| Dec 31, 2010 | -6.19% |
| Sep 30, 2010 | 1,777.21% |
| Jun 30, 2010 | 2,508.08% |